Saxena White P.A. Files Securities Fraud Class Action Against Delcath Systems, Inc.

Saxena White P.A. Files Securities Fraud Class Action Against Delcath Systems, 
Inc. 
BOCA RATON, FL -- (Marketwired) -- 06/17/13 --  Saxena White P.A. has
filed a securities fraud class action lawsuit in the United States
District Court for the Southern District of New York against Delcath
Systems, Inc. ("Delcath" or the "Company") (NASDAQ: DCTH) and certain
of the Company's executive officers. The class action is filed on
behalf of investors who purchased or otherwise acquired Declath's
common stock during the period from April 21, 2010 and May 2, 2013,
inclusive (the "Class Period"). The complaint brings claims for
violations of the Securities Exchange Act of 1934. 
Delcath operates as a specialty pharmaceutical and medical device
company focusing on the field of oncology. The Company's proprietary
technology purportedly enables the administration of high-dose
chemotherapy and other therapeutic agents to diseased organs or
regions of the body, while controlling the systemic exposure of those
agents.  
The Complaint alleges that throughout the Class Period, Defendants
made false and/or misleading statements, as well as failed to
disclose material adverse facts about the Company's business,
operations, and prospects. Specifically, Defendants made false and/or
misleading statements and/or failed to disclose that: (1) the
Company's New Drug Application ("NDA") for its Melblez Kit (consists
of a drug (melphalan) and a device bundled together in a single
package) for the treatment of patients with unresectable ocular
melanoma metastatic to the liver contained risks including
substantial and severe toxicity and deaths associated with the drug's
adverse reactions; and (2) the Company's manufacturing facilities
were in violation of Current Good Manufacturing Practices.  
You may obtain a copy of the complaint and join the class action at
www.saxenawhite.com. If you purchased Delcath stock between April 21,
2010 and May 2, 2013, inclusive, you may contact Joe White
(jwhite@saxenawhite.com) or Marc Grobler (mgrobler@saxenawhite.com)
at Saxena White P.A. to discuss your rights and interests. 
If you purchased Delcath common stock during the Class Period of
April 21, 2010 through May 2, 2013, and wish to apply to be the lead
plaintiff in this action, a motion on your behalf must be filed with
the Court no later than July 8, 2013. You may contact Saxena White
P.A. to discuss your rights regarding the appointment of lead
plaintiff and your interest in the class action. Please note that you
may also retain counsel of your choice and need not take any action
at this time to be a class member. 
Saxena White P.A., located in Boca Raton, specializes in prosecuting
securities fraud and complex class actions on behalf of institutions
and individuals. Currently serving as lead counsel in numerous
securities fraud class actions nationwide, the firm has recovered
hundreds of millions of dollars on behalf of injured investors and is
active in major litigation pending in federal and state courts
throughout the United States. 
Joseph E. White, III
jwhite@saxenawhite.com 
Marc Grobler
mgrobler@saxenawhite.com 
Saxena White P.A.
2424 North Federal Highway, Suite 257
Boca Raton, FL 33431
Tel: (561) 394-3399
Fax: (561) 394-3382
www.saxenawhite.com